REPLIMUNE GROUP, INC. Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
REPLIMUNE GROUP, INC. (REPL) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $93.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2020-02-13.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-02-13
- REPLIMUNE GROUP, INC. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-06-30 was $93.00K.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month |
|---|---|
| 2019-06-30 | $93.00K 10-Q · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |